Annovis Says 'The Interim Analysis Was Based On 107 Patients At 6 Weeks From All Cohorts Collectively And Showed That The Ad Trial Should Continue As Planned With The Same Trial Size To Maintain The Statistical Power For Both Co-Primary Endpoints.'
Portfolio Pulse from Bill Haddad
Annovis Bio Inc. has announced that the interim analysis of their Alzheimer's Disease (AD) trial, based on 107 patients at 6 weeks, has shown positive results. The trial will continue as planned with the same size to maintain the statistical power for both co-primary endpoints.
October 12, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Annovis Bio's ongoing AD trial shows promising results in the interim analysis, which could potentially boost investor confidence in the company.
Positive results from clinical trials often lead to increased investor confidence as they indicate potential future success of the product. This could lead to an increase in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100